A registered EARLY_PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- EARLY Phase 1
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 210
- Population
- ALL · 70 Years to 85 Years
- Duration
- 2023-04-24 to 2027-12-31
- Intervention
- FMT capsules; Placebo capsules
- Comparator
- Placebo capsules
- Outcomes measured
- Proportion of participants with reduced frailty score at week 96 follow-up — week 96; Proportion of participants with reduced frailty score at week 12 follow-up — week 12; Proportion of participants with reduced frailty score at week 24 follow-up — week 24; Proportion of participants with reduced frailty score at week 48 follow-up — week 48; Proportion of participants with reduced frailty score at week 72 follow-up — week 72; Change from baseline in Frailty score — week 12, week 24, week 48, week 72, week 96, compared with baseline; Change from baseline in telomere length — week 48, week 96; Change from baseline in Cognitive assessment via Mini Mental State Examination(MMSE) — week 24, week 48, week 72, week…; Change from baseline in Cognitive assessment via Montreal Cognitive Assessment(MoCA) — week 24, week 48, week 72, week…; Change from baseline in Hippocampal volumes — week 48, week 96; Change from baseline in cognitive biomarkers — week 12, week 24, week 48, week 72, week 96; Change from baseline in inflammatory biomarkers — week 12, week 24, week 48, week 72, week 96; Change from baseline in Intestinal Microbiota Composition Pre- and Post-intervention via Metagenomic Analysis — week 12…; Change from baseline in Intestinal Microbiota Function assessed by KEGG Orthology (KO) Pre- and Post-intervention via M…; Change from baseline in Plasma Metabolite Composition Pre- and Post-intervention via Metabolomic Analysis — week 12, we…; Change from baseline in Ankle-Brachial Blood Pressure Index(ABI) — week 48, week 96; Change from baseline in Pulse wave velocity(PWV) — week 48, week 96; Number of Participants with Adverse Events (AEs) as a Measure of Safety — week 12, week 24, week 48, week 72, week 96; Change from baseline in Body Mass Index (BMI) — week 4, week 8, week 12, week 24, week 48, week 72, week 96; Change from baseline in office SBP — week 4, week 8, week 12, week 24, week 48, week 72, week 96
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Microbiome and dysbiosis · 100%Title contains controlled term: microbiome. Abstract contains controlled term: microbiome. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.